Catalyst Wire Dossier Catalyst Wire Dossier

DTG/3TC

dolutegravir/lamivudine · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for DTG/3TC, covering 2019-12-09 to 2025-12-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF [Phase 3]

See pricing